Search result for 'biocon biologics'

Biocon's net profit doubled to Rs 344 crore in Q4 FY25, driven by strong sales across business verticals. Total revenue also increased year-on-year.

Biocon Biologics secures multiple market access agreements in the US for its biosimilar, Yesintek, for treating Crohn's disease, ulcerative colitis, psoriasis, and psoriatic arthritis.

Biocon Biologics has secured market entry for its biosimilar product Yesafili in the US after reaching a settlement agreement with Regeneron. Yesafili, a biosimilar of Eylea (aflibercept), will be...

Biocon Biologics receives USFDA approval for Jobevne (bevacizumab-nwgd), a biosimilar Bevacizumab for treating various cancers. This approval expands the company's biosimilar oncology portfolio in...

Biocon Biologics partners with Civica Inc to increase affordability and access to Insulin Aspart in the US, targeting the 38.4 million Americans with diabetes.

Biocon Biologics launches YESINTEK (ustekinumab-kfce), a biosimilar for Crohn's disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis, in the US market.

India's Competition Commission has penalized Goldman Sachs' investment manager for not notifying a deal to acquire a stake in Biocon Biologics, citing potential strategic impact.

Biocon Biologics' Bengaluru drug substance facility has been classified as voluntary action indicated by the USFDA following a cGMP inspection. The action relates to rh-Insulin (rhI) drug substance...

Biocon Biologics refinances USD 1.1 billion long-term debt through dollar bonds and a new syndicated facility, strengthening its capital structure and fueling long-term growth.

Biocon Biologics has reached an agreement with Janssen to launch its biosimilar medication for autoimmune diseases in Europe, Canada, and Japan. The settlement clears the way for commercialization...

Biocon's Q1 profit jumps six-fold to Rs 660 crore, driven by a one-time gain from the Biocon Biologics and Eris Lifesciences collaboration. Revenue also grew slightly.

Eris Lifesciences reports a 4.5% decline in consolidated profit after tax to Rs 89 crore for Q1 FY25, while revenue rose to Rs 720 crore. The company expects significant growth in its Biocon business.

Biocon Biologics receives approval from the EMA to manufacture biosimilar Bevacizumab at its Bengaluru facility, expanding capacity for European markets. The company also received GMP certificates...

Biocon Biologics has received USFDA approval for Yesafili, a biosimilar to Eylea (aflibercept), for treating various ophthalmology conditions like age-related macular degeneration.

Biocon's consolidated net profit declined by 57% to Rs 136 crore in Q4 FY24, while revenue rose marginally to Rs 3,966 crore. The company's total expenses increased.

Biocon Biologics secures patent settlement, paving the way for the launch of Yesafili, a biosimilar to Eeylea (aflibercept) injection, in Canada by July 1, 2025.

Biocon Biologics has secured a licence to commercialize its biosimilar product to treat psoriasis, Crohn's disease, and ulcerative colitis in the US.

Biocon Biologics and Sandoz have partnered to distribute two biosimilar cancer treatment products, Ogivri (Trastuzumab) and Abevmy (Bevacizumab), in Australia.

Biocon posted a consolidated net profit of Rs 660 crore for the third quarter ended December 31, 2023, driven by strong sales. The company's revenue also grew significantly.

Biocon Biologics has partnered with Sandoz to exclusively market Adalimumab BS for subcutaneous injection, indicated for immune-related diseases, in Japan.

Biocon Biologics completes integration of Viatris' biosimilar business in 31 European countries, expanding access to lifesaving treatments.

Biocon Biologics has sold its dermatology and nephrology branded formulations business units in India to Eris Lifesciences for Rs 366 crore. The deal is expected to close by the end of November 2023.